Please use this identifier to cite or link to this item: http://docs.prosentient.com.au/prosentientjspui/handle/1/10798
Title: Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis.
Authors: Besada, Emilio
Koldingsnes, Wenche
Nossent, Johannes C
Affiliation: Bone and Joint Research Group, Institute of Clinical Medicine, University of Tromsø, Rheumatology Department, University Hospital of North Norway, Tromsø, Norway and Division of Medicine, Royal Darwin Hospital, Department of Health, Darwin, NT, Australia. emilio.besada@unn.no..
Bone and Joint Research Group, Institute of Clinical Medicine, University of Tromsø, Rheumatology Department, University Hospital of North Norway, Tromsø, Norway and Division of Medicine, Royal Darwin Hospital, Department of Health, Darwin, NT, Australia..
Bone and Joint Research Group, Institute of Clinical Medicine, University of Tromsø, Rheumatology Department, University Hospital of North Norway, Tromsø, Norway and Division of Medicine, Royal Darwin Hospital, Department of Health, Darwin, NT, Australia. Bone and Joint Research Group, Institute of Clinical Medicine, University of Tromsø, Rheumatology Department, University Hospital of North Norway, Tromsø, Norway and Division of Medicine, Royal Darwin Hospital, Department of Health, Darwin, NT, Australia..
Issue Date: Oct-2014
Citation: Rheumatology (Oxford, England) 2014-10; 53(10): 1818-24
Abstract: Rituximab (RTX) is a B cell depleting agent used to induce and maintain remission in patients with granulomatosis with polyangiitis (GPA). As the development of hypogammaglobulinaemia in GPA patients on long-term RTX has not been addressed, the aim of this study was to investigate changes in immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term RTX maintenance therapy in GPA. We used a single-centre cohort study of 29 GPA patients who received a median total cumulative dose of CYC of 17 g and were treated with 2 g RTX followed by re-treatment with either 2 g once annually, 1 g biannually or a combination of both. Ig levels were measured before each RTX re-treatment and hypogammaglobulinaemia was defined as levels of total immunoglobulin <6 g/l. During a median follow-up of 4 years, patients received a cumulative dose of 9 g RTX. While serum Ig levels decreased during RTX maintenance, the largest decrease occurred after the first infusion. Baseline Ig levels and the CYC cumulative dose predicted Ig levels, whereas the RTX cumulative dose did not. Eight patients (28%) discontinued RTX due to hypogammaglobulinaemia. Male gender [hazard ratio (HR) = 8.7, P = 0.044], kidney involvement (HR = 6.5, P = 0.083) and the 1 g biannual regimen (HR = 8.0, P = 0.024) increased the risk to discontinue RTX due to hypogammaglobulinaemia, whereas orbital-subglottic involvement (HR = 0.23, P = 0.080) decreased it. Hypogammaglobulinaemia occurred in one-quarter of GPA patients during RTX maintenance, independent of the RTX cumulative dose. Male gender, kidney involvement and the 1 g biannual RTX regimen constitute risk factors for severe hypogammaglobulinaemia necessitating withdrawal of RTX.
URI: http://docs.prosentient.com.au/prosentientjspui/handle/1/10798
DOI: 10.1093/rheumatology/keu194
Type: Journal Article
Subjects: ANCA-associated vasculitis
B cell
Hypogammaglobulinaemia
granulomatosis with polyangiitis
immunoglobulins
maintenance
rituximab
safety
Adolescent
Adult
Agammaglobulinemia
Aged
Antibodies, Monoclonal, Murine-Derived
Child
Female
Granulomatosis with Polyangiitis
Humans
Immunoglobulins
Immunologic Factors
Male
Middle Aged
Registries
Remission Induction
Retrospective Studies
Risk Factors
Rituximab
Treatment Outcome
Young Adult
Appears in Collections:NT Health digital library

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.